Displaying 553 (all) recruiting clinical trials.
-
Impact of Weight Loss in Patients with Hypertrophic Cardiomyopathy
This is an observational imaging study to evaluate the cardiac effects of weight loss in obese patients with a BMI >=30 with a confirmed diagnosis ... -
Gut microbiome alterations as a mechanism of immune dysregulation in new-onset refractory status epilepticus (NORSE)
We will perform a prospective, observational cohort study, with biospecimen collection, of NORSE subjects and subjects with status epilepticus of known cause (e.g. epilepsy ... -
Gut Microbiome in Food Protein-Induced Enterocolitis Syndrome: An Observational Study
Food protein-induced enterocolitis syndrome (FPIES) is a non IgE-mediated food allergy that manifests with predominantly gastrointestinal symptoms and usually starts in the first year of ... -
NEW YORK OSTEOARTHRITIS HAND COHORT
This is an observational, longitudinal registry of patients with hand osteoarthritis (HOA) that broadly aims to assess the clinical spectrum, risk factors, and identify possible ... -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Nivolumab will be investigated at the Food and Drug Administration (FDA)-approved dose of 480 mg intravenous (IV) every 4 weeks until unacceptable toxicity, disease ... -
AALL1732 A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
The purpose of the study is to determine the safety and efficiency of the investigational medicine Inotuzumab Ozogamicin for patients who have NCI high risk ...
-
AALL1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494 NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
This is a Children's Oncology Group (COG) phase 3 trial for children (ages 1-25 years) newly diagnosed with high risk B-lymphoblastic leukemia (HR B-ALL ... -
GBM AGILE TRIAL
Glioblastoma adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies ... -
Site for Abaloparatide versus Placebo for Pelvic Fracture Healing - A Phase 2 Randomized Controlled Trial
Site for This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men = 50 years ... -
A single-center prospective observational study of post-discharge outcomes and function among patients treated for severe COVID-19 disease
This is a single-center observational study that aims to examine physical and mental function of patients treated for severe COVID-19 disease at NYU Langone Health ...